Further Information Disclaimer
Home
Referring Centers
For Patients
Publications
disclaimer


MATERNAL AGE IS THE MOST IMPORTANT PARAMETER PREDICTING ANEUPLOIDY YET IT IS AN UNPREDICTABLE INDICATOR OF CHROMOSOME ABNORMALITIES

Munné S, Escudero T, Colls P, Zheng X, Cinnioglu C, Cohen
Reprogenetics, West Orange, NJ

Introduction: The increase of aneuploidy with maternal age has been demonstrated both with live birth, fetus, embryos and oocyte data. In contrast, post-meiotic abnormalities such as mosaicism, polyploidy, and haploidy, are constant around 30% regardless of maternal age. However, age is only a gross indicator of chromosome abnormalities and there seems to be great variation within ages. The purpose of this study was to evaluate such variation.

Methods: Patients undergoing IVF and PGD for aneuploidy using probes for 9 chromosomes were included in this retrospective study. Cycles with 4 or less embryos were not included. The IVF cycle was performed in 88 different IVF clinics, and the PGD analysis performed by Reprogenetics.

Results: Results are summarized in the below table. Overall, 31% of embryos were normal, with a maximum average of 42% below age 30 and a minimum average   of 23% above age 39. However, 20% of young patients had less than 25% normal embryos and 5% of women 40 and older had more than 50% normal ones.

 

% normal
age cycles 100-76% 75-51% 50-26% 25-0% average
18-29 225 6% 22% 52% 20% 42.3%
30-34 443 4% 20% 48% 28% 38.5%
35-39 1075 1% 13% 51% 34% 34.2%
40-up 966 0% 5% 34% 61% 23.4%
total 2709 2% 12% 45% 41% 31.7%

 

Discussion: The high rate of chromosome abnormalities in human embryos may warrant PGD for all IVF cycles, provided that the selection advantage of PGD compensates for the potential damage caused by the biopsy or biospies. The alternative is to not involve PGD for aneuploidy with the likely result of unpredictable rates and high order


PGD BREAKING NEWS
2/2006 High rates of chromosome abnormalities are found in embryos from egg donors, suggesting that PGD may be recommended in egg donor cycles.
Embryo chromosome studies show high rates of abnormalities, above 50%, but most embryos studied before this study were from patients 35 and older. | Read
Reprogenetics demonstrates that patients with recurrent pregnancy loss can benefit from PGD
The objective of the study was to determine if Preimplantation Genetic Diagnosis (PGD) and transfer of chromosomally normal embryos would decrease spontaneous abortion rates in patients suffering from recurrent pregnancy loss (RPL).   | Read
See the abstracts presented by Reprogenetics at the PGDIS meeting (London)
Microarray technology to assess gene expression profiles... |
Read

PGD DIAGNOSIS
Reprogenetics provides PGD analysis to IVF centers, including PGD of aneuploidy for advanced maternal age (such as Down syndrome), repeated IVF failure, recurrent spontaneous abortions, chromosome translocations and inversions, as well as PGD for gene defects such as Cystic fibrosis, fragile X, Myotonic Dystrophy, Thalasaemia, Tay Sachs, and others. We also provide embryologist that can perform embryo biopsy and cell processing.  
GENETIC COUNSELING FOR PATIENTS
Patients interested in PGD services could contact an IVF center for which we provide services or directly contact our genetic counselor for an in depth discussion of your case.
ASSOCIATIONS
www.IVFonline.com
www.LifeGlobal.com
www.ivflabs.com


MORE STORIES
Reprogenetics obtains a license to perform PGD in NY state for any type of PGD
Dear Colleague: In July of 2003, laboratories and assisted reproductive technology (ART) providers were notified that a New York State laboratory permit would be required for facilities performing preimplantation genetic diagnosis (PGD) on single cells derived from embryos by molecular genetic and/or cytogenetic techniques. |
Read

HOME >>>
 

Reprogenetics
© Copyright 2001 Janus Net Technology, Inc. All rights reserved.
Refering IVF Centers Home Contact Us Further Information Disclaimers about PGD